MacroGenics, Inc. announced on June 10, 2025, that it has entered into a royalty purchase agreement with Sagard Healthcare Partners. Under the terms, MacroGenics received a $70 million upfront payment for the sale of a capped royalty interest on future global net sales of ZYNYZ (retifanlimab-dlwr).
MacroGenics will retain its other economic interests related to ZYNYZ, including future potential development, regulatory, and commercial milestones. Sagard will collect royalties until aggregate payments totaling $140 million are received, after which MacroGenics will resume collecting all future royalties.
This $70 million upfront payment, combined with the company's cash, cash equivalents, and marketable securities balance of $154.1 million as of March 31, 2025, and projected future payments from partners, is expected to extend MacroGenics' cash runway into the first half of 2027.
The agreement provides significant non-dilutive funding, bolstering MacroGenics' financial flexibility. This enhanced liquidity is crucial for funding planned investments in the company's ongoing clinical and preclinical programs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.